文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

新兴的吸入气溶胶装置和策略:我们将走向何方?

Emerging inhalation aerosol devices and strategies: where are we headed?

机构信息

Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, 2006 NSW, Australia.

Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, 2006 NSW, Australia; Respiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Sydney Medical School, The University of Sydney, 2037 NSW. Australia.

出版信息

Adv Drug Deliv Rev. 2014 Aug;75:3-17. doi: 10.1016/j.addr.2014.03.006. Epub 2014 Apr 13.


DOI:10.1016/j.addr.2014.03.006
PMID:24732364
Abstract

Novel inhaled therapeutics including antibiotics, vaccines and anti-hypertensives, have led to innovations in designing suitable delivery systems. These emerging design technologies are in urgent demand to ensure high aerosolisation performance, consistent efficacy and satisfactory patient adherence. Recent vibrating-mesh and software technologies have resulted in nebulisers that have remarkably accurate dosing and portability. Alternatively, dry powder inhalers (DPIs) have become highly favourable for delivering high-dose and single-dose drugs with the aid of advanced particle engineering. In contrast, innovations are needed to overcome the technical constrains in drug-propellant incompatibility and delivering high-dose drugs with pressurised metered dose inhalers (pMDIs). This review discusses recent and emerging trends in pulmonary drug delivery systems.

摘要

新型吸入性疗法,包括抗生素、疫苗和抗高血压药物,推动了合适的给药系统的设计创新。这些新兴设计技术迫切需要确保高雾化性能、一致的疗效和令人满意的患者依从性。最近的振动网和软件技术已经产生了具有显著精确剂量和便携性的雾化器。另一方面,干粉吸入器(DPIs)在借助先进的颗粒工程来输送高剂量和单剂量药物方面变得非常受欢迎。相比之下,需要创新来克服药物-推进剂不相容性和使用压力定量吸入器(pMDIs)输送高剂量药物的技术限制。本文综述了肺部药物输送系统的最新和新兴趋势。

相似文献

[1]
Emerging inhalation aerosol devices and strategies: where are we headed?

Adv Drug Deliv Rev. 2014-4-13

[2]
[Aerosol therapy].

Schweiz Med Wochenschr. 1998-8-15

[3]
Aerosol drug delivery: developments in device design and clinical use.

Lancet. 2010-10-29

[4]
Inhalatory therapy training: a priority challenge for the physician.

Acta Biomed. 2007-12

[5]
New inhaler devices - the good, the bad and the ugly.

Respiration. 2014

[6]
100 Years of Drug Delivery to the Lungs.

Handb Exp Pharmacol. 2019

[7]
Metered-dose inhalers, dry powder inhalers, and transitions.

Respir Care. 2000-6

[8]
Metered dose inhalers: current and future uses.

Br J Clin Pract Suppl. 1997-5

[9]
The inhalation of drugs: advantages and problems.

Respir Care. 2005-3

[10]
New liquid aerosol generation devices: systems that force pressurized liquids through nozzles.

Respir Care. 2002-12

引用本文的文献

[1]
Inhalable Nanotechnology-Based Drug Delivery Systems for the Treatment of Inflammatory Lung Diseases.

Pharmaceutics. 2025-7-9

[2]
[Advances in inhalable nano-formulations].

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2025-7-3

[3]
Exploring the Potential of PLGA Nanoparticles for Enhancing Pulmonary Drug Delivery.

Mol Pharm. 2025-7-7

[4]
Formulation of Bacteriophage for Inhalation to Treat Multidrug-Resistant Pulmonary Infections.

Kona. 2025

[5]
Different Carriers for Use in Dry Powder Inhalers: Characteristics of Their Particles.

J Aerosol Med Pulm Drug Deliv. 2024-12

[6]
Dry powder inhaler design and particle technology in enhancing Pulmonary drug deposition: challenges and future strategies.

Daru. 2024-12

[7]
Nano-Formulations for Pulmonary Delivery: Past, Present, and Future Perspectives.

Pharmaceutics. 2024-1-24

[8]
A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review).

Int J Oncol. 2024-4

[9]
Excipients for Novel Inhaled Dosage Forms: An Overview.

AAPS PharmSciTech. 2024-2-14

[10]
A Novel Combined Dry Powder Inhaler Comprising Nanosized Ketoprofen-Embedded Mannitol-Coated Microparticles for Pulmonary Inflammations: Development, In Vitro-In Silico Characterization, and Cell Line Evaluation.

Pharmaceuticals (Basel). 2024-1-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索